Metastatic Breast Cancer Clinical Trials in Lisbon
4 recruitingLisbon, Portugal
Showing 1–4 of 4 trials
Recruiting
Phase 3
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+2 more
West German Study Group250 enrolled7 locationsNCT07281833
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 2
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Metastatic Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc.150 enrolled53 locationsNCT06369285
Recruiting
Not Applicable
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
Metastatic Breast Cancer
Breast International Group1,000 enrolled52 locationsNCT02102165